Exosome vs PDRN: Two Skincare Terms Compared
Exosomes are particles that cells release. PDRN, short for polydeoxyribonucleotide, is a DNA-based ingredient. They are different things that now often sit together on one product label.
The evidence for both is preliminary, and we declare no winner.
Last reviewed October 15, 2026
Side by side
| Topic | Exosomes | PDRN |
|---|---|---|
| What it is | Tiny particles wrapped in a membrane that cells release, carrying proteins, fats and genetic material | Polydeoxyribonucleotide, fragments of DNA used as a skincare ingredient |
| What the label may say | "Exosomes", "extracellular vesicles", sometimes with a source such as plant, milk or bacteria | "PDRN", "sodium DNA"; the maker we read describes salmon DNA |
| Evidence | Preliminary: 19 human studies in a 2026 review, mostly not randomized | Seven randomized trials with 183 participants in a 2026 review, small and varied |
| FDA | No exosome product is FDA approved | We make no regulatory claim about PDRN |
What each one is
Exosomes belong to the family of extracellular vesicles: particles enclosed in a membrane that carry proteins, lipids and nucleic acids between cells. Many aesthetic products and studies call such preparations exosomes even when an exosome origin is not shown. (PMID 42353255)
PDRN is a DNA-derived ingredient. The Medicube page we read describes salmon DNA fragments, and lists "Sodium DNA" in the ingredient list of its PDRN exosome shot, next to extracellular vesicles and milk exosomes. (Medicube PDRN Pink Collagen Exosome Shot page)
What studies show
A 2026 systematic review of PDRN trials found seven randomized trials with 183 participants. Four looked at skin rejuvenation. Overall they reported better wrinkle-related outcomes, scar quality and satisfaction, with no serious treatment-related adverse events. The review mixes several indications, and its abstract does not state how the products were applied. The authors note small samples, varied protocols and a need for larger trials. (PMID 42572627)
A 2026 narrative review of PDRN after skin procedures describes the human evidence as a mix of randomized trials, cohort studies and split-face trials, with few randomized aesthetic trials, small samples and formulas that differ. (PMID 42299173)
For exosomes see the evidence guide. None of the studies we cite compares the two head to head.
What the rules say
For exosomes, the FDA said in 2019 that there are no FDA-approved exosome products. (FDA notice, December 6, 2019) We make no claim about the regulatory status of PDRN. For how the FDA treats skincare in general, see the FDA status guide.
Reading a label that has both
A bottle that lists both exosomes and PDRN is a blend, and any effect belongs to the whole formula. Check the full ingredient list, not just the front of the box. Our label guide shows how.
Quick answers
What is the difference between exosomes and PDRN?
Exosomes are membrane-wrapped particles released by cells. PDRN is a DNA-based ingredient. Some skincare products list both.
Which is better, exosomes or PDRN?
None of the studies we cite compares them head to head, so we cannot name one. The evidence for each is preliminary.
Sources
This page has not yet been reviewed by a licensed clinician. Sources are listed below. Last editorial check: October 15, 2026.
- 2026 narrative review of extracellular vesicles in aesthetic medicine, PubMed, PMID 42353255
- 2026 systematic review of PDRN trials, PubMed, PMID 42572627
- 2026 narrative review of PDRN after skin procedures, PubMed, PMID 42299173
- Medicube US, PDRN Pink Collagen Exosome Shot product page, read October 15, 2026
- FDA public safety notification on exosome products, December 6, 2019